SCHEMBL17108554

SCHEMBL17108554

Cc1ccnc(C(C)C(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.48
CCR1 P32246 1/20 0.48
CCR5 P51681 1/20 0.48
CCR8 P51685 1/20 0.48
KDM4E B2RXH2 3/20 0.45
NOS2 P35228 3/20 0.45
KMT2A Q03164 3/20 0.45
NOS3 P29474 2/20 0.45
NOS1 P29475 2/20 0.45
MEN1 O00255 2/20 0.45
PLAU P00749 1/20 0.37
HRH1 P35367 1/20 0.36
CXCR4 P61073 1/20 0.36
FDPS P14324 1/20 0.36
CYP2A6 P11509 1/20 0.35
METAP2 P50579 1/20 0.35
CRHR1 P34998 2/20 0.34
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL179530 0.82 UHRF1 (0.52) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL29453940 0.82 UHRF1 (0.52) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL20116282 0.79 UHRF1 (0.45) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL26271662 0.79 UHRF1 (0.45) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL4428487 0.78 NOS2 (0.50) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL643383 0.78 UHRF1 (0.48) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL18149357 0.78 UHRF1 (0.48) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL1706587 0.78 UHRF1 (0.48) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL18519477 0.78 UHRF1 (0.48) UHRF1CCR1CCR5CCR8KDM4E
SCHEMBL28749349 0.78 NOS2 (0.50) UHRF1CCR1CCR5CCR8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066758-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH 2017-03-09 US disclosed
US-9233979-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-12 US disclosed
US-20150266895-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266895-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK10, MAP3K1 UHRF1 2471/4885CCR1 3628/4885CCR5 3429/4885
US-20170066758-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION HDGF, HCCS, BCAT1 UHRF1 538/4885CCR1 4065/4885CCR5 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.